Veru

Veru Inc. is a U.S.-based biopharmaceutical company that develops therapies targeting women's health, urology, oncology, and infectious diseases. It is publicly traded on the NASDAQ under the ticker VERU. The company operates a portfolio of product candidates in preclinical to late-stage clinical development, with sabizabulin as its lead program. Sabizabulin is a tubulin inhibitor designed to disrupt cancer cell division and has been investigated for oncology indications and for severe COVID-19 in clinical studies. In addition to sabizabulin, Veru pursues other drug candidates addressing urological and gynecological conditions, as well as companion diagnostics and formulation improvements. Veru has engaged in collaborations and licensing arrangements to support its pipeline and to expand development and commercialization capabilities. The company reports its progress and trial results in periodic filings with the U.S. Securities and Exchange Commission and presents updates to investors and analysts. As with other biotechnology firms, Veru's pipeline is subject to clinical trial outcomes, regulatory review, and market dynamics, which affect valuation and future prospects.